(firstQuint)Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis.

 This is a multicenter, double-blinded, randomized, placebo-controlled clinical trial to investigate the efficacy and safety of berberine on subjects with Non-alcoholic Steatohepatitis.

Patients with biopsy-proven non-alcoholic steatohepatitis (NASH) from 18-65 years of age were enrolled.

 Patients should had no excessive alcohol intake or use of any hepatoprotective or hepatotoxicity medication within 3 months before enrollment.

Patients will have an screening period 12 weeks, and a 48-week double-blinded treatment period.

.

 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis@highlight

The purpose of this study is to evaluate the efficacy and safety of berberine treatment on Non-alcoholic Steatohepatitis.

